{"id":"https://openalex.org/W2992251663","doi":"https://doi.org/10.14309/01.ajg.0000613108.75253.69","title":"P035 Defining Responders for the Crohn\u2019s Disease Patient-Reported Outcomes Signs and Symptoms (CD-PRO/SS) Tool Using Data From Patients Treated With Etrolizumab","display_name":"P035 Defining Responders for the Crohn\u2019s Disease Patient-Reported Outcomes Signs and Symptoms (CD-PRO/SS) Tool Using Data From Patients Treated With Etrolizumab","publication_year":2019,"publication_date":"2019-12-01","ids":{"openalex":"https://openalex.org/W2992251663","doi":"https://doi.org/10.14309/01.ajg.0000613108.75253.69","mag":"2992251663"},"language":"en","primary_location":{"id":"doi:10.14309/01.ajg.0000613108.75253.69","doi":"https://doi.org/10.14309/01.ajg.0000613108.75253.69","is_oa":false,"landing_page_url":"https://doi.org/10.14309/01.ajg.0000613108.75253.69","pdf_url":null,"source":{"id":"https://openalex.org/S66441642","display_name":"The American Journal of Gastroenterology","issn_l":"0002-9270","issn":["0002-9270","1572-0241"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Gastroenterology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070320149","display_name":"Peter Higgins","orcid":"https://orcid.org/0000-0003-1366-4028","observed_orcids":["https://orcid.org/0000-0003-1366-4028"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Higgins","raw_affiliation_strings":["University of Michigan, Ann Arbor, MI;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Michigan, Ann Arbor, MI;","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087320027","display_name":"Kendra P.A. DeBusk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kendra DeBusk","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103879397","display_name":"Rhian Jacob","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rhian Jacob","raw_affiliation_strings":["Roche Products Limited, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Products Limited, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I4210113058"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057469165","display_name":"Azra Hassanali","orcid":"https://orcid.org/0000-0001-5883-5658","observed_orcids":["https://orcid.org/0000-0001-5883-5658"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Azra Hassanali","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018439866","display_name":"Zaineb Sharafali","orcid":"https://orcid.org/0000-0002-4189-1132","observed_orcids":["https://orcid.org/0000-0002-4189-1132"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zaineb Sharafali","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067596939","display_name":"Young S. Oh","orcid":"https://orcid.org/0000-0001-5445-2860","observed_orcids":["https://orcid.org/0000-0001-5445-2860"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Young Oh","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084867240","display_name":"Alysha K. Kadva","orcid":"https://orcid.org/0000-0002-2637-8373","observed_orcids":["https://orcid.org/0000-0002-2637-8373"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alysha Kadva","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112143195","display_name":"Alison Matsui","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alison Matsui","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"114","issue":"1","first_page":"S9","last_page":"S9"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crohn-s-disease","display_name":"Crohn's disease","score":0.9980000257492065},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.9150000214576721},{"id":"https://openalex.org/keywords/responder-definition","display_name":"responder definition","score":0.7480000257492065},{"id":"https://openalex.org/keywords/etrolizumab","display_name":"etrolizumab","score":0.972000002861023},{"id":"https://openalex.org/keywords/minimal-clinically-important-difference","display_name":"minimal clinically important difference","score":0.7049999833106995},{"id":"https://openalex.org/keywords/anti-tnf-naive-patients","display_name":"anti-TNF-naive patients","score":0.7200000286102295},{"id":"https://openalex.org/keywords/disease-activity","display_name":"disease activity","score":0.36500000953674316},{"id":"https://openalex.org/keywords/inflammatory-bowel-disease-questionnaire","display_name":"IBDQ","score":0.7770000100135803},{"id":"https://openalex.org/keywords/crohn-s-disease-activity-index","display_name":"CDAI","score":0.9940000176429749},{"id":"https://openalex.org/keywords/treatment-effect-assessment","display_name":"treatment effect assessment","score":0.3449999988079071},{"id":"https://openalex.org/keywords/clinical-trial-endpoints","display_name":"clinical trial endpoints","score":0.3179999887943268}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9497910141944885},{"id":"https://openalex.org/C2779280984","wikidata":"https://www.wikidata.org/wiki/Q1472","display_name":"Crohn's disease","level":3,"score":0.6704418659210205},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6703811287879944},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6403859853744507},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6164617538452148},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6115249395370483},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.576774537563324},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4688728153705597},{"id":"https://openalex.org/C2778260677","wikidata":"https://www.wikidata.org/wiki/Q917447","display_name":"Inflammatory bowel disease","level":3,"score":0.46372291445732117},{"id":"https://openalex.org/C2779517570","wikidata":"https://www.wikidata.org/wiki/Q7144954","display_name":"Patient-reported outcome","level":3,"score":0.4554363191127777},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.417632132768631},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.3669678568840027},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3219236433506012},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.26505106687545776},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.1593247950077057},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.15916159749031067},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.14309/01.ajg.0000613108.75253.69","doi":"https://doi.org/10.14309/01.ajg.0000613108.75253.69","is_oa":false,"landing_page_url":"https://doi.org/10.14309/01.ajg.0000613108.75253.69","pdf_url":null,"source":{"id":"https://openalex.org/S66441642","display_name":"The American Journal of Gastroenterology","issn_l":"0002-9270","issn":["0002-9270","1572-0241"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Gastroenterology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2912249398","https://openalex.org/W2944222735","https://openalex.org/W2802175013","https://openalex.org/W2944473764","https://openalex.org/W6939994691","https://openalex.org/W2334959221","https://openalex.org/W3107522405","https://openalex.org/W2161723853","https://openalex.org/W2977857071","https://openalex.org/W4362586561"],"abstract_inverted_index":{"BACKGROUND:":[0],"Clinically":[1],"relevant":[2],"patient-reported":[3],"outcome":[4,92],"(PRO)":[5],"tools":[6],"are":[7,199,437],"important":[8,256],"for":[9,28,87,106,130,334,357,363,373,380,386,470,484],"assessing":[10],"the":[11,17,34,47,60,81,97,109,131,144,229,232,239,273,282,296,335,339,350,358,364,374,381,387,411,415,421,424,435,443,449,454,458,471,477],"effect":[12],"of":[13,20,37,104,108,122,204,209,231,241,244,269,293,347,368,402,440],"a":[14,90,102,177,214,219,267,345,377,430,438,494],"treatment":[15,369],"on":[16,266,344,410,434],"clinical":[18,42,74,91,118,482,488],"course":[19],"Crohn\u2019s":[21,51,62,283],"disease":[22,38,117],"(CD).":[23],"Available":[24],"PRO":[25,64],"instruments":[26],"used":[27],"CD":[29,139,161],"have":[30],"limitations":[31],"in":[32,114,143,272,281,442,448,476,486],"evaluating":[33],"full":[35],"extent":[36],"components,":[39],"appropriately":[40],"quantifying":[41],"symptoms,":[43],"and":[44,56,73,76,84,157,184,218,251,263,278,331,338,361,384,400,414,464,490],"adequately":[45],"capturing":[46],"patient":[48],"perspective.":[49],"The":[50,120,206,223],"Disease":[52,276,284],"Patient-Reported":[53,461],"Outcomes":[54,462],"Signs":[55,463],"Symptoms":[57,465],"(CD-PRO/SS)":[58],"is":[59,77],"first":[61],"disease\u2013specific":[63],"tool":[65],"developed":[66],"with":[67,137,141,160,164,314],"input":[68],"from":[69,135,200,299,321,352],"health":[70],"authorities,":[71],"patients,":[72],"experts":[75],"under":[78],"review":[79],"by":[80,406,457],"US":[82],"Food":[83],"Drug":[85],"Administration":[86],"validation":[88],"as":[89,111,228],"measure.":[93],"In":[94,151,420],"April":[95],"2019,":[96],"European":[98],"Medicines":[99],"Agency":[100],"released":[101],"letter":[103],"support":[105],"use":[107,485],"CD-PRO/SS":[110,132,207,297,375,436,472],"an":[112],"endpoint":[113],"inflammatory":[115],"bowel":[116,221,340,365,388,416,450],"trials.":[119],"aim":[121],"this":[123],"study":[124],"was":[125,226],"to":[126,396,453,492],"define":[127],"responder":[128,426],"definitions":[129,372,427,469],"using":[133,238,261],"data":[134,316],"patients":[136,159,202,301,403],"moderate-to-severe":[138],"treated":[140,163],"etrolizumab":[142,165,479],"BERGAMOT":[145],"Phase":[146,480],"3":[147,481],"trial":[148],"(NCT02394028).":[149],"METHODS:":[150],"BERGAMOT,":[152],"anti-tumor":[153],"necrosis":[154],"factor":[155],"(aTNF)\u2013naive":[156],"aTNF-experienced":[158],"were":[162,189,236,259,317,326,355,376,391,404],"105":[166],"mg,":[167,169],"210":[168],"or":[170,446],"placebo":[171],"subcutaneously":[172],"every":[173],"4":[174],"weeks":[175],"during":[176],"14-week":[178],"induction":[179],"phase.":[180],"Cohort":[181],"1":[182],"(blinded)":[183],"cohort":[185,304,309],"2":[186,210],"(open-label":[187],"etrolizumab)":[188],"analyzed":[190],"independently;":[191],"those":[192],"cohorts":[193],"included":[194],"all":[195,201],"treatments.":[196],"Data":[197],"presented":[198],"regardless":[203,367],"treatment.":[205],"consists":[208],"separately":[211],"scored":[212],"scales:":[213],"3-item":[215,220],"functional":[216,336,359,382,412,444],"domain":[217,224,337,360,366,383,389,413,445],"domain.":[222,451],"score":[225],"calculated":[227,260],"sum":[230],"item":[233],"scores,":[234],"which":[235],"derived":[237],"average":[240],"\u22654":[242],"out":[243],"7":[245],"days":[246],"before":[247],"week":[248,252,289,324,407],"0":[249],"(baseline)":[250],"14.":[253,290],"Minimum":[254],"clinically":[255,431,495],"differences":[257],"(MCIDs)":[258],"distributional-":[262],"anchor-based":[264,353],"methods":[265],"reduction":[268,346,378,439],"\u226516":[270],"points":[271,280],"Inflammatory":[274],"Bowel":[275],"Questionnaire":[277],"\u2265100":[279,348],"Activity":[285],"Index":[286],"(CDAI)":[287],"at":[288,323],"RESULTS:":[291],"As":[292],"September":[294],"2018,":[295],"scores":[298],"479":[300],"(67.4%":[302],"aTNF-experienced;":[303],"1,":[305],"n":[306,311],"=":[307,312],"215;":[308],"2,":[310],"264)":[313],"nonmissing":[315],"analyzed.":[318],"Mean":[319],"changes":[320],"baseline":[322],"14":[325,408],"\u22122.28":[327],"(standard":[328],"deviation,":[329],"2.55)":[330],"\u22122.45":[332],"(2.89)":[333],"domain,":[341,417],"respectively.":[342,418],"Based":[343],"CDAI,":[349],"MCIDs":[351],"method":[354],"2.7":[356],"3.1":[362],"arm.":[370],"Responder":[371],"\u22652.5":[379,441],"\u22653.0":[385,447],"that":[390,429],"determined":[392],"through":[393],"triangulation.":[394],"According":[395],"these":[397,467],"cutoffs,":[398],"44%":[399],"40%":[401],"responders":[405,455],"based":[409],"CONCLUSION(S):":[419],"pooled":[422],"analysis,":[423],"proposed":[425],"demonstrate":[428],"meaningful":[432,496],"response":[433],"Similar":[452],"defined":[456],"Ulcerative":[459],"Colitis":[460],"tool,":[466],"preliminary":[468],"will":[473],"be":[474],"validated":[475],"ongoing":[478],"trials":[483,489],"both":[487],"practice":[491],"assess":[493],"improvement.":[497]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-12-13T00:00:00"}